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cm or larger. A dose of about 4500 rad is
given in 4-5 weeks, followed by another
1500-2000 rad given by arc therapy to a
smaller volume which is largely determined
by the appearance of the chest x-ray 4 weeks
after the treatment began. The total treat-
ment time is of the order of 6 weeks. It is
difficult to estimate the described dosage
accurately, since it is always given as a
number of rads, the field size and overall
time being rarely mentioned. It is assumed
that dosage is based on an input rate of
1000 rad per week.
This treatment policy is very different
from British practice, which is based on
the principle of higher doses to smaller
volumes of tissue, and therefore limits
radical treatment to earlier cases. For this
reason the radiotherapy section of the book
is not of value to British students of radio-
therapy, though the remainder of the book
is a useful contribution to the literature.
E. SHERRAH-DAVIES
Cell Survival after low Doses of Radia-
ation: Theoretical and Clinical Impli-
cations. Proceedings ofthe 6th L. H. Gray
Conference, London, 1974. Ed. T. ALPER
(1975). Institute of Physics: John Wiley.
Pp. xiv + 397. Price £13.50 net.
It has taken the majority of radio-
biologists about 18 years to concentrate
their attention on dose-cell survival relation-
ships in the therapeutic range of 200-300 rad
per fraction. This omission can now be
corrected with the proceedings of this
conference, where these relationships were
discussed rigorously. Forty-five contributed
papers were arranged in 6 sessions, ranging
from fundamental aspects to clinical applica-
tions. The influence of the physical sciences
in biology is shown vividly in this conference:
20% of the 142 participants had Physics or
Medical Physics departmental addresses.
The first two sessions dealt with the statistical
problems involved in measuring small frac-
tions ofcell killing, and with biomathematical
models for cell survival as a function of
dose.
The critical lesion for cell death (if indeed
there is only one type applicable to the
whole cell survival curve) is still unknown,
but DNA breaks and consequent chromo-
some breaks are implicated to a great
extent and are at the head of the current
list. At least 7 dose-response relationships
for cell survival are mentioned-these are
usually 2- or 3-parameter functions and their
biophysical basis and degree of fit to experi-
mental data are the main criteria for accept-
ance and use for comparative purposes and
interpretation. Thus, a " good " model in
this field combines two virtues: few variables
and low chi-squared. Nearly all cell survival
data show an initial slope at low dose,
i.e. there is no true threshold. How much
of this, if any, is due to the inhomogeneity
of the radiation dose at the molecular level,
or the presence of a radiosensitive fraction
of cells, is not fully known.
Modifications to the initial slope by 02
and other chemical sensitizers are described
at length. Results vary from simple dose
modification to unexpected protection at
very low doses, and definitive experiments
are hampered by the technical difficulties
involved in these measureinents. The scope
ofthe meeting was large enough to encompass
other cells than mammalian (e.g. bacteria,
plant cells, yeast) and other radiations than
x-rays (e.g. 125I, u.v., neutrons).
Tumour cell responses for low dose in vivo
irradiations are covered with respect to
dose-rate, fractionation and high pressure
02. The difference in response ofchronically
and acutely hypoxic cells, and the important
question of whether hypoxic cells really
are a major problem in human tumour
radiotherapy, were discussed but still remain
unexplained.
The interpretation of multi-fraction ex-
periments on normal tissues formed the
final session. A cell survival curve can be
deduced from multi-fraction data when
certain assumptions are made, but it must
not be forgotten that this is the " effective "
cell survival curve for dose fractionation,
which may differ, for many reasons, from
that determined for single exposures in a
well controlled situation. Therefore, the
interpretation in terms of the same model
functions has inherent problems. Repopula-
tion during fractionation is allowed for in
such a deduction, and this is of course
unnecessary, or at least easier, with the
slow turnover tissues (e.g. lung, kidney),
than with the rapidly regenerating haemo-
poietic and epithelial tissues.
The conference as a whole, although with
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of radiobiology and cell survival and their
application to therapy. The hardback edi-
tion increases the price unnecessarily, especi-
ally as it could well have been published
in a Review series. Apart from the serious
omission of pages 339-340 and 365-366 from
two of the four copies I have seen, the book
(with complete pagination) is recommended
as an up-to-date review of the state of this
art.
J. H. HENDRY
Cancer Therapy: Prognostic Factors and
Criteria of Response. Ed. M. J. STAQUET
(1975). Amsterdam: North Holland. Pp.
xii + 393. Price £10.26 net.
Cancer chemotherapy is now expanding
rapidly due to the elaboration of combination
schedules and the introduction of new
drugs. It is of prime importance therefore,
that clinical trials are conducted correctly
to assess the response to therapy. This
book brings together the expertise and
knowledge of prominent workers in the
field of cancer therapy who, between them,
have produced a valuable text for any
clinician involved in assessing cytotoxic
drugs.
The book is well written and contains
ample figures and tables. There are 21
chapters. The first 3 are devoted to method-
ology and I found the section on statistical
methods for survival studies particularly
interesting. The following 6 chapters are
devoted to the lympho-reticular disorders,
all well covered, with the possible exception
of the chapter devoted to non-Hodgkin's
lymphoma. The remaining chapters are
devoted to solid tumours. Each chapter
details criteria for response and appropriate
parameters for assessment, followed by a
comprehensive bibliography.
The book is strongly recommended to
cancer chemotherapists, and also to radio-
therapists. It is probably too specialized
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for other specialities but should find a place
in the appropriate library.
P. M. WILKINSON
Characterisation of Human Tumours.
Ed. W. DAVIS and C. MALTONI (1974).
Amsterdam: Excerpta Medica. Pp. 335.
Price $42.30 net.
This volume is the first of a series on
"Advances in Tumour Prevention, Detection
and Characterisation ", edited by C. Maltoni,
in which it is intended to include critical
reviews, experimental studies and symposia.
It contains the proceedings of the 5th
International Symposium held at Bologna,
Italy in 1973 on the characterization of
humantumours. Theprogramme was varied
and it struck a good balance between clinical
and experimental research. The reports
are divided into chapters covering biological
aspects of carcinogenesis, the role of viruses
in human cancer, chemical carcinogenesis,
mammary tumours (a particularly interesting
chapter), immunology and experimental and
clinical studies. Each chapter contains at
least one review lecture given by an expert
in his chosen field; these are well written
and we are given a fascinating series of
viewpoints ranging from a consideration
of molecular interactions at the cell surface
to epidemiological aspects of mammary
tumours. These papers could serve as an
introductory source ofreferences and provide
a concise survey of many important aspects
of present-day cancer research.
The majority of the contributions are
not reviews but original papers. There is
no doubt of the scientific merit of these
reports, but it is debatable whether these
studies alone would be reason enough for
buying the book since most of the data
should now be published in detail in specialist
journals.
G. W. BAZILL